Adial Pharma Reports Executive/Director Changes, Comp Arrangements
Ticker: ADIL · Form: 8-K · Filed: Jan 18, 2024 · CIK: 1513525
| Field | Detail |
|---|---|
| Company | Adial Pharmaceuticals, Inc. (ADIL) |
| Form Type | 8-K |
| Filed Date | Jan 18, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $25,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Adial Pharma just filed an 8-K about executive changes and compensation, watch for strategic shifts.**
AI Summary
Adial Pharmaceuticals, Inc. filed an 8-K on January 18, 2024, reporting an event that occurred on January 17, 2024, related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers'. This filing indicates changes in the company's leadership or executive compensation structure. For investors, this matters because changes in key personnel or their compensation can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.
Why It Matters
Changes in leadership or executive compensation can significantly influence a company's strategic direction and operational efficiency, directly affecting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Changes in executive leadership or compensation can introduce uncertainty regarding future company performance and strategic direction, posing a medium risk to investors.
Analyst Insight
Investors should monitor subsequent filings or company announcements for specific details regarding the personnel changes and compensation arrangements to assess their potential impact on Adial Pharmaceuticals' future strategy and financial health.
Key Players & Entities
- ADIAL PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
- January 17, 2024 (date) — date of the earliest event reported
- January 18, 2024 (date) — date the 8-K was filed
FAQ
What specific items are being reported in this 8-K filing by Adial Pharmaceuticals, Inc.?
Adial Pharmaceuticals, Inc. is reporting on 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits' as per the ITEM INFORMATION section of the filing.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 17, 2024, as stated in the 'Date of Report (date of earliest event reported): January 17, 2024' section.
What is the business address of Adial Pharmaceuticals, Inc. as listed in the filing?
The business address of Adial Pharmaceuticals, Inc. is 1180 Seminole Trail, Suite 495, Charlottesville, VA 22901, according to the filing's BUSINESS ADDRESS section.
What is the Commission File Number for Adial Pharmaceuticals, Inc.?
The Commission File Number for Adial Pharmaceuticals, Inc. is 001-38323, as indicated in the filing.
What is the primary industry classification for Adial Pharmaceuticals, Inc.?
Adial Pharmaceuticals, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification (SIC) in the FILER COMPANY DATA section.
Filing Stats: 767 words · 3 min read · ~3 pages · Grade level 10.8 · Accepted 2024-01-18 16:15:23
Key Financial Figures
- $25,000 — of the Corporation at a compensation of $25,000 per month and devote no less than 75% o
Filing Documents
- ea191817-8k_adialpharma.htm (8-K) — 40KB
- ea191817ex10-2_adialpharma.htm (EX-10.2) — 30KB
- ea191817ex99-1_adialpharma.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-004505.txt ( ) — 271KB
- adil-20240117.xsd (EX-101.SCH) — 3KB
- adil-20240117_lab.xml (EX-101.LAB) — 33KB
- adil-20240117_pre.xml (EX-101.PRE) — 22KB
- ea191817-8k_adialpharma_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 18, 2024 ADIAL PHARMACEUTICALS, INC. By: /s/ Cary J. Claiborne Name: Cary J. Claiborne Title: President and Chief Executive Officer * * * 2